Put a New Publication Into Appropriate Scientific Context

A new trial publication drops on a Friday afternoon, and by Monday a physician has already formed an opinion from the abstract alone. You get the call before you finish your own read of the paper. This is one of the most common conversations a medical science liaison has, and it is also one of the easiest to get wrong. Handle it well and you help a clinician think more clearly about the evidence in front of them. Handle it poorly and you either sound evasive or you slide into telling someone how to treat their patients.

Why this conversation goes wrong

Most clinicians do not read full papers before forming a view. They read the abstract, they read a headline from a medical news site, or a colleague sends them the conclusion line with no other context. By the time they reach you, they already have an opinion, and your job is not to argue with that opinion. It is to help them examine the paper itself.

The pressure runs the other way too. You want to sound knowledgeable and current, so there is a pull to summarize the paper's conclusion as if it settles something. That pull is dangerous. A single study rarely settles anything, and repeating the authors' own framing without naming the limitations they listed does the clinician a disservice. On the other end, if you hedge on everything and refuse to describe what the study actually found, you sound unhelpful and the clinician stops asking you for anything beyond reprints.

The real difficulty sits in the middle. You have to describe the paper accurately, name what it does and does not show, and stop short of telling the clinician what to do with a patient. That line is easy to state and hard to hold in a live conversation, especially when someone is pushing you for a straight answer.

How to prepare

Read the full paper before the conversation happens, not just the abstract and the discussion section. Reprints and abstracts get forwarded faster than you can prepare, so build a habit of reading new publications in your therapeutic area within a day or two of release, before a clinician calls you about one.

When you prepare, work through a short list every time.

1. Note the study population, the design, and the primary endpoint, and write down how they differ from the patients the clinician actually treats.
2. List the limitations the authors state themselves, in their own discussion section, rather than limitations you infer.
3. Identify two or three related papers that support, qualify, or contradict this one, so you have something to offer beyond the single source.
4. Check whether the publication touches on safety findings that require a different kind of response. If it does, treat that part of the conversation with the same care described in Respond to Safety Information in a Scientific Email.

This preparation matters more than any phrase you plan to use in the moment. A liaison who has actually read the methods section sounds different from one who is paraphrasing an abstract, and clinicians notice the difference quickly.

What to say

Start by naming what you understand the clinician's view to be, then ask what part of the paper shaped it. This does two things. It shows you are listening, and it gets the conversation onto the actual text rather than a secondhand summary.

Dr. Patel says, "This new paper seems to settle the question on first line sequencing." You say, "What in the paper made you land there?" She points to the conclusion line in the abstract. You walk through the enrolled population, the primary endpoint, and the two limitations the authors name in their own discussion, including a short follow up period. You say, "The authors are careful to note that their follow up was under two years. That matters if you're thinking about durability of response." Dr. Patel asks whether any other studies point the same direction. You describe two related papers she can read side by side with this one, and you tell her plainly that how this applies to her patients is her call to make, not yours.

Notice what happens in that exchange. You never say the study is wrong or right. You never tell her what to prescribe. You give her the tools to read the paper the way the authors intended it to be read, with its own stated limits attached. That is the entire job in this conversation.

Mistakes to avoid

The most common mistake is repeating the abstract conclusion as if it were the full finding. Abstracts compress a paper for space, and the compression often drops caveats that matter. Read the limitations section every time and bring it into the conversation, even when nobody asks for it.

A second mistake is offering an opinion on how the paper should change practice. That is not your role, and clinicians will remember if you cross it, especially if a compliance question ever comes up later. Describe the evidence and stop there.

A third mistake is treating every new paper as decisive. One study rarely overturns years of prior evidence, and saying so plainly, without hedging into vague language, actually builds trust rather than undermining it.

A fourth mistake shows up when a publication includes an unexpected safety finding buried in the results. Rushing past it to get to the primary endpoint is a bad habit. A publication with a safety signal deserves the same discipline covered in Respond to a Safety Signal Discussion With Precisionwhere naming the finding clearly matters more than moving the conversation along quickly.

How to practice and score it

This conversation is worth rehearsing out loud, not just reading about. Ask a colleague or your manager to play a clinician who has already decided the paper proves more than it does, and push back the way a busy physician actually would, with a direct claim and not much patience for nuance. Run the exchange twice, once where you over commit to the conclusion and once where you hedge on everything, so you can hear how each version sounds from the other side of the table.

Score the attempt against a few concrete markers. Did you name the study population and design without being asked. Did you state a limitation the authors themselves raised, not one you invented. Did you avoid any sentence that told the clinician what to do with a specific patient. Did you offer at least one related reference instead of treating the single paper as the whole picture.

DealSpeak builds this exact scenario into its rehearsal sessions, scoring your responses against those same markers so you can see where a conversation slipped into overstatement or evasiveness before it happens with a real clinician. If you want more scenarios built around this kind of exchange, the Pharmaceuticals practice conversations hub has a full set built for medical science liaisons.

A new publication is not a test of your opinion. It is a chance to help a clinician read carefully, and the liaisons who do this well are the ones who describe the evidence with precision and let the clinician draw their own conclusion.